ClinicalTrials.gg
RecruitingNCT05837221Updated Feb 24, 2026

Microbiome in Head and Neck Squamous Cell Carcinoma

An observational study in Head and Neck Cancer, Lip Cancer and Oral Cancer, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by University of Colorado, Denver · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Head and Neck Neoplasms by University of Colorado, Denver — 4 open to participants now, 6 under way, none of them phase 3. Head and Neck Neoplasms · University of Colorado, Denver.

Started
2025
with 1 other
Observational
2 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Head and Neck Neoplasms by University of Colorado, Denver, this one is one of 2 that started in 2025, is one of 2 observational ones, and was the 10th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

4 of the 12 studies in Head and Neck Neoplasms by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Head and Neck Neoplasms by University of Colorado, Denver, or all of them as a file.
02

Study summary

This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.

Read the detailed description

HNSCCis a lethal cancer with a 5-year survival rate below 50%. Although smoking, alcohol intake, and human papillomavirus (HPV) infection are linked to HNSCC, only a small proportion of individuals exposed to these factors develop cancer and not all cases progress. Thus, additional environmental or host factors must contribute to HNSCC. The Study Team and others have observed significant oral dysbiosis in human HNSCC cases, both before and after treatment. This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.

03

Conditions studied

  • Head and Neck Cancer
  • Lip Cancer
  • Oral Cancer
  • Pharynx Cancer
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

We aim to enroll 60 patients total - 30 with oral squamous cell carcinoma (OSCC) who are treatment naïve, and 30 who are non-OSCC control patients, who will be age matched to their OSCC counterparts. Estimates show that Dr. Goddard's practice sees approximately 3 treatment naïve OSCC cases per month. We estimate that we can enroll 30-40 of these cases and an equal number of controls in the first 18 months of this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects equal to or above the age of 18.
  2. Patients who are seen and evaluated by a provider within the adult Otolaryngology clinic at the University of Colorado Health.
  3. Patients that present with a diagnosis of OSCC.
  4. An equal number of age-matched patients who are visiting the clinic for reasons other than OSCC diagnoses, as the control group.
  5. Ability to understand and willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  1. Subjects under the age of 18 or over the age of 100
  2. Subjects unwilling to particiapte
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Oral Squamous Cell Carcinoma Saliva Sample Group

    Saliva will be collected at least 30 minutes after subjects stop eating, drinking, chewing gum, and smoking. Subjects will be instructed to spit saliva into a collection tube. The saliva will be split into two aliquots, one that is immediately frozen at -80C and one that is mixed 1:1 with pre-reduced tryptic soy broth, L-cysteine, and glycerol then frozen at -80C to preserve the viability of microorganisms.

    Diagnostic Test: Metagenomic sequencing · Diagnostic Test: Metabolic analysis

  • Non Oral Squamous Cell Carcinoma Saliva Sample Group

    Saliva will be collected at least 30 minutes after subjects stop eating, drinking, chewing gum, and smoking. Subjects will be instructed to spit saliva into a collection tube. The saliva will be split into two aliquots, one that is immediately frozen at -80C and one that is mixed 1:1 with pre-reduced tryptic soy broth, L-cysteine, and glycerol then frozen at -80C to preserve the viability of microorganisms.

    Diagnostic Test: Metagenomic sequencing · Diagnostic Test: Metabolic analysis

  • Oral Squamous Cell Carcinoma Stool Sample Group

    Stool collection methods may differ depending on the patient. The aim is to collect fresh stool samples, those that are available will be collected during the study visit. If a patient is unable to give a sample at the visit, samples may be collected at home using the OMNIgene-GUT and OMNImet-GUT kits (DNA Genotek, Inc.).

    Diagnostic Test: Metagenomic sequencing · Diagnostic Test: Metabolic analysis

  • Non Oral Squamous Cell Carcinoma Stool Sample Group

    Stool collection methods may differ depending on the patient. The aim is to collect fresh stool samples, those that are available will be collected during the study visit. If a patient is unable to give a sample at the visit, samples may be collected at home using the OMNIgene-GUT and OMNImet-GUT kits (DNA Genotek, Inc.).

    Diagnostic Test: Metagenomic sequencing · Diagnostic Test: Metabolic analysis

Interventions

  • Diagnostic testMetagenomic sequencing

    Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.

  • Diagnostic testMetabolic analysis

    Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host

06

What researchers measure

Primary outcomes

  1. Characterize human dysbiosis

    Stool and saliva samples will be collected from participants, allowing us to reproduce human dysbiosis and analyze whether HNSCC affects one's microbiome composition. Metagenomic sequencing will be conducted through use of DNA extraction, library generation and Illumina sequencing. At least 30 million paired-end 2x150bp metagenomic reads will be generated per sample using the Illumina NovaSeq platform.

    Time frame: Day 1

  2. Characterize human metabolomics

    Through our stool and saliva samples we will be able to characterize metagenomic and metabolic signatures in treatment naïve OSCC and non-OSCC patients. Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 componds including Trp pathway products, while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host and metabolic and immune statuses.

    Time frame: Day 1

  3. Integrative multi-omic data analysis and biomarker discovery

    We expect to find that specific sets of microbial and host factors interact with each other to promote OSCC.

    Time frame: Day 365

Secondary outcomes

  1. Impact of human dysbiosis on OSCC development in mice

    Freshly collected saliva and stool samples from 10 subjects of each treatment category will be used to reconstitute microbiota.

    Time frame: Day 10-Day 100

  2. Monitor tumor size

    Tumor size (both weight and size) will be monitored using Bli-imaging. These measures will be assessed between treatment groups by ANOVA or analysis of variance testing.

    Time frame: Day 10-Day 100

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Of 216 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 18 months is below that.

Counting every sponsor, half of 238 studies reached it within 69 months; a quarter within 29 and three quarters within 144.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2023
First posted
May 1, 2023
StartActual
May 23, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Oct 2028
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05837221
Responsible party
Sponsor
First posted
May 1, 2023
Start date
May 23, 2025
Primary completion
Nov 2026 (estimated)
Completion
Oct 2028 (estimated)
Last update
Feb 24, 2026

Study contacts

Yosr Doghri
Contact
yosr.doghri@cuanschutz.edu
(303) 724-6550
Kristi Engle Folchert
Contact
kristi.englefolchert@cuanschutz.edu
(303) 724-9528
Shi-Long E Lu, MD, PhD
principal investigator · University of Colorado, Denver

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion